$56.41 -$0.07 (-0.1%)

04:00 PM EST on 11/20/19

Bristol-Myers Squibb Co. (NYSE:BMY)

CAPS Rating: 4 out of 5

Bristol-Myers Squibb discovers, develops, licenses, makes, and sells pharmaceuticals, with particular success in cardiovascular treatments.

Current Price $56.41 Mkt Cap $92.0B
Open $56.15 P/E Ratio 16.32
Prev. Close $56.48 Div. (Yield) $1.64 (2.9%)
Daily Range $55.30 - $56.50 Volume 90,857,792
52-Wk Range $42.49 - $59.17 Avg. Daily Vol. 12,799,698

Caps

How do you think NYSE:BMY will perform against the market?

Add Stock to CAPS Watchlist

All Players

1,759 Outperform
118 Underperform
 

All-Star Players

356 Outperform
20 Underperform
 

Wall Street

23 Outperform
4 Underperform
 

Top NYSE:BMY Bull/Bear Pitches

The best Bull and Bear pitches based on recency and number of recommendations.

steelbreeze1753 (70.89)
Submitted January 25, 2019

Non-cyclical, at least to the economy, which does well in a Bear Market (which we now are in).

msabol01 (66.21)
Submitted April 02, 2017

Strong pipeline and a culture that wants to innovate. Strong focus on patients. Leadership seems to struggle with launching products and being competitive out the door. Long term will either find BMY on strong footing or acquired.

Recent Community Commentary

Read the most recent pitches from players about BMY.

Recs

0
Member Avatar NewCap (< 20) Submitted: 9/26/2019 3:53:42 PM : Outperform Start Price: $49.44 NYSE:BMY Score: +9.58

The prospective high growth for the next fiscal years is among the main assets of the company
The company is in a robust financial situation considering its net cash and margin position.
Upward revisions of sales forecast reflect a renewed optimism among the analysts covering the stock.
Over the past year, analysts have regularly revised upwards their sales forecast for the company.
For the past twelve months, EPS forecast has been revised upwards.
For the past year, analysts covering the stock have been revising their EPS expectations upwards in a significant manner.
Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock

Recs

0
Member Avatar JohnnyMac28 (67.55) Submitted: 8/14/2019 12:03:40 PM : Outperform Start Price: $45.87 NYSE:BMY Score: +14.08

healthcare play

Recs

0
Member Avatar TMFBigFrog (92.95) Submitted: 7/18/2019 11:43:58 PM : Outperform Start Price: $43.82 NYSE:BMY Score: +25.14

Looks reasonably cheap after adjusting for Celgene acquisition.

Leaderboard

Find the members with the highest scoring picks in BMY.

Score Leader

d3lta4ce

d3lta4ce (30.84) Score: +255.45

The Score Leader is the player with the highest score across all their picks in BMY.

Top
Pick
Member Name Member
Rating
Start
Date
Call Time
Frame
Start
Price
Stock
Gain
Index
Gain
Score Commentary
99FE905 20.93 6/20/2008 Outperform 5Y $12.88 +338.10% +141.97% +196.13 0 Comment
tkaskmaster 47.94 6/23/2008 Outperform 3M $12.89 +337.65% +142.71% +194.93 0 Comment
Nacho2k 80.41 6/13/2008 Outperform 3Y $13.06 +331.95% +137.10% +194.84 0 Comment
SandmanKy 84.20 6/13/2008 5/8/2015 Outperform 5Y $12.99 +334.34% +139.55% +194.78 1 Comment
tylerfu 65.98 6/13/2008 Outperform 5Y $12.99 +334.34% +139.55% +194.78 0 Comment
tnovosad < 20 6/13/2008 Outperform NS $13.07 +331.52% +136.88% +194.64 0 Comment
snowape 75.93 6/18/2008 Outperform 3Y $12.98 +334.45% +140.50% +193.95 1 Comment
cyberDEAD < 20 6/20/2008 Outperform 1Y $12.97 +335.01% +141.10% +193.91 0 Comment
CLF65 34.91 6/24/2008 9/8/2009 Outperform 1Y $12.88 +338.10% +144.41% +193.69 0 Comment
bigbird0459 < 20 6/11/2008 Outperform NS $13.05 +332.16% +138.54% +193.62 0 Comment

Wall Street

See what the Wall Street professionals think, according to their public statements and filings.

There are no Wall Street tracker picks for BMY.